NCT03791216Completed
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 62 (actual)
- First submitted
- 5 Dec 2018
- Start date
- 1 Dec 2018
- Primary completion date
- 18 Jun 2025
- Lead sponsor
- Northwestern University
- Diseases
- Psoriasis
- NCT number
- NCT03791216
What you commit to
- Study type: Observational
- Participants enrolled: 62
- From 1 Dec 2018 to the primary completion date, 18 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have other systemic inflammatory diseases (including atopic dermatitis, severe acne, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue diseases and/or other autoimmune diseases).
- Patients who have active infection or malignancy or have suffered from infection requiring oral or parenteral antibiotic in past 2 weeks.
Lab values
- Patients with congenital heart disease, prior cardiac catheterizations/surgeries, or on cardiac medications in the past two years other than for hypertension (eg, calcium channel-blockers, beta-blockers and vasotropic medications).
Age
- Patients less than 6 years of age or 18 years and older
Other
- Patients and parents/caregivers unable to give written informed consent.
Who the study is looking for
- Children ages 6-17 years of all races/ethnicities with plaque and/or extensive guttate psoriasis for at least 6 months and on topical or systemic therapy
- Patients in the systemic group can be starting a medication for the first time OR transitioning from another systemic if unresponsive and on that previous treatment for ≤ 3 months.
- Patients may concurrently have psoriatic arthritis if initiation of a systemic medication is warranted by skin severity.
- Children ages 6-17 years of all races/ethnicities with acne being treated with isotretinoin
- Children ages 6-17 years of all races/ethnicities without plaque or guttate psoriasis and history of severe acne or treatment with isotretinoin as controls.
Age in the registry: 6 years to 17 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.